公开(公告)号：US4321376A

公开(公告)日：1982-03-23

申请号：US101126

申请日：1979-12-07

申请人： Masaru Otani ,  Satoshi Yaginuma ,  Masatoshi Tsujino ,  Naoki Muto ,  Tetsu Saito ,  Tadashiro Fujii

发明人： Masaru Otani ,  Satoshi Yaginuma ,  Masatoshi Tsujino ,  Naoki Muto ,  Tetsu Saito ,  Tadashiro Fujii

IPC分类号： C07D473/34 ,  A61K31/52 ,  A61P25/24 ,  A61P25/26 ,  A61P35/00 ,  C07D473/00 ,  C12P17/18 ,  C12P19/40 ,  C12R1/01 ,  C12R1/645 ,  C07D473/32

CPC分类号： C07D473/00 ,  C12P19/40 ,  C12R1/01

摘要： Neplanocin-B and -F of the formula ##STR1## in which Y is oxygen or a valence bond, are produced by culturing Ampullariella sp. A 11079 FERM-P No. 4494 in a nutrient medium and then separating the neplanocin-B and -F thus produced from the culture medium.

摘要翻译： 其中Y为氧或价键的式“IMAGE”的Neplanocin-B和-F通过培养Ampullariella sp。 在营养培养基中的11079FERM-P No.4494，然后从培养基中分离由此产生的奈普兰诺B和-F。

公开(公告)号：US3919226A

公开(公告)日：1975-11-11

申请号：US47879974

申请日：1974-06-12

申请人： BOEHRINGER MANNHEIM GMBH

发明人： THIEL MAX ,  FRIEBE WALTER-GUNAR ,  STACH KURT ,  ROESCH EGON ,  ROESCH ANDRONIKI

IPC分类号： C07D473/34 ,  A61K31/41 ,  A61K31/52 ,  C07D241/04 ,  C07D295/12 ,  C07D403/12 ,  C07D473/32

CPC分类号： C07D473/00 ,  Y10S514/87

摘要： WHEREIN R1 is hydrogen or lower alkyl; R2 is phenyl or benzyl, optionally substituted by halogen, lower alkyl or lower alkoxy; and A is lower alkylene optionally substituted by a hydroxyl group; AND THE PHARMACOLOGICALLY COMPATIBLE SALTS THEREOF; HAVE OUTSTANDING ANTI-OEDEMA, ANTI-INFLAMMATORY AND ANTI-ALLERGIC ACTIVITY.

New purine compounds of the formula

摘要翻译： 式WHEREIN R1的新嘌呤化合物是氢或低级烷基; R2是苯基或苄基，任选被卤素，低级烷基或低级烷氧基取代; A是任选被羟基取代的低级亚烷基; 及其药理学兼容性; 具有抗病毒，抗炎和抗过敏活性。

公开(公告)号：US12018002B2

公开(公告)日：2024-06-25

申请号：US17506367

申请日：2021-10-20

申请人： NEUPHARMA, INC

发明人： Xiangping Qian ,  Yong-Liang Zhu

IPC分类号： C07D239/74 ,  A61K45/06 ,  C07D239/84 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D471/04 ,  C07D473/32 ,  C07D487/04

CPC分类号： C07D239/74 ,  A61K45/06 ,  C07D239/84 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D471/04 ,  C07D473/32 ,  C07D487/04

摘要： Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.

公开(公告)号：US11987584B2

公开(公告)日：2024-05-21

申请号：US18074746

申请日：2022-12-05

申请人： Ribon Therapeutics, Inc.

发明人： Laurie B. Schenkel ,  Melissa Marie Vasbinder ,  Kevin Wayne Kuntz ,  Nicholas Robert Perl ,  Jennifer Downing

IPC分类号： C07D487/04 ,  A61P35/00 ,  C07D403/10 ,  C07D417/10 ,  C07D471/04 ,  C07D473/32 ,  C07D495/04 ,  C07D513/04

CPC分类号： C07D487/04 ,  A61P35/00 ,  C07D403/10 ,  C07D417/10 ,  C07D471/04 ,  C07D473/32 ,  C07D495/04 ,  C07D513/04

摘要： The present invention relates to heterobicyclic amides and related compounds which are inhibitors of CD38 and are useful in the treatment of cancer.

公开(公告)号：US11884671B2

公开(公告)日：2024-01-30

申请号：US16973862

申请日：2019-06-14

申请人： ASTRAZENECA AB ,  CANCER RESEARCH TECHNOLOGY LIMITED

发明人： Maurice Raymond Verschoyle Finlay ,  Frederick Woolf Goldberg ,  Martin Richard Howard ,  Attilla Kuan Tsuei Ting

IPC分类号： C07D473/32 ,  A61K9/127 ,  A61K31/437 ,  A61K31/502 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/704 ,  A61N5/10

CPC分类号： C07D473/32 ,  A61K9/127 ,  A61K31/437 ,  A61K31/502 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/704 ,  A61N5/10 ,  C07B2200/13

摘要： The specification generally relates to compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, where R, A1, A2 and A3 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.

公开(公告)号：US20230158035A1

公开(公告)日：2023-05-25

申请号：US18095670

申请日：2023-01-11

申请人： Signal Pharmaceuticals, LLC

发明人： Matthew Alexander ,  Sogole Bahmanyar ,  John Frederick Boylan ,  Joshua Hansen ,  Dehua Huang ,  Robert Hubbard ,  Brandon Jeffy ,  Jim Leisten ,  Mehran Moghaddam ,  Raj K. Raheja ,  Heather Raymon ,  Kimberly Schwarz ,  Marianne Sloss ,  Eduardo Torres ,  Tam Minh Tran ,  Shuichan Xu ,  Jingjing Zhao

IPC分类号： A61K31/52 ,  C07D473/32 ,  A61P35/00 ,  A61K31/5377

CPC分类号： A61K31/52 ,  C07D473/32 ,  A61P35/00 ,  A61K31/5377

摘要： Provided herein are Aminopurine Compounds having the following structures:






wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.

公开(公告)号：US20230111132A1

公开(公告)日：2023-04-13

申请号：US17787152

申请日：2020-12-21

申请人： The Regents of the University of California

发明人： Kevan M. Shokat ,  Ziyang Zhang

IPC分类号： A61K39/00 ,  C07D403/12 ,  C07D239/48 ,  C07D473/18 ,  C07D473/16 ,  C07D473/32 ,  C07D473/24 ,  C07F9/6561 ,  G01N33/53

摘要： Provided, inter alia, are methods and compositions for treating cancer.

公开(公告)号：US11612602B2

公开(公告)日：2023-03-28

申请号：US17001147

申请日：2020-08-24

申请人： ACEA Therapeutics, Inc.

发明人： Xiao Xu ,  Xiaobo Wang ,  Long Mao ,  Li Zhao ,  Biao Xi

IPC分类号： A61K31/519 ,  C07D403/12 ,  A61P35/00 ,  A61K31/52 ,  C07D473/32 ,  A61K31/506 ,  C07D487/04 ,  C07D401/14 ,  C07D473/34 ,  A61K45/06 ,  C07D239/48 ,  C07D473/24 ,  C07D239/46 ,  C07D473/40 ,  C07D239/42 ,  C07D487/02 ,  C07D473/16 ,  C07D239/47 ,  C07D401/12

摘要： The present disclosure provides pharmaceutical compounds, compositions and methods, especially as they are related to compositions and methods for the treatment of tumors and related diseases related to the dysregulation of kinase (such as EGFR (including HER), Alk, PDGFR, but not limited to) pathways.

公开(公告)号：US11337981B2

公开(公告)日：2022-05-24

申请号：US16886290

申请日：2020-05-28

申请人： SRI INTERNATIONAL

发明人： Thomas R. Webb ,  Jaehyeon Park ,  Chandraiah Lagisetti

IPC分类号： C07D473/16 ,  A61K31/52 ,  A61P35/00 ,  C07D473/32 ,  A61K31/437 ,  C07D487/04

摘要： The disclosure generally relates to substituted purine analogs that are dual CLK2/CDK1 inhibitors or more potent and specific CLK inhibitors to target CLK2 and CDK1 kinases. These compounds may be useful in the treatment of germ-line mutations of the spliceosome leading to the development of cancers and other human disease. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US20220098198A1

公开(公告)日：2022-03-31

申请号：US17371857

申请日：2021-07-09

申请人： Primmune Therapeutics, Inc.

发明人： Stephen E. Webber ,  James Richard Appleman

IPC分类号： C07D473/18 ,  C07D473/32

摘要： The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.